首页> 外文期刊>The Primary Care Companion to CNS Disorders >Combination of Clozapine With Long-Acting Injectable Antipsychotics in Treatment-Resistant Schizophrenia: Preliminary Evidence From Health Care Utilization Indices
【24h】

Combination of Clozapine With Long-Acting Injectable Antipsychotics in Treatment-Resistant Schizophrenia: Preliminary Evidence From Health Care Utilization Indices

机译:氯氮平联合长效注射抗精神病药治疗难治性精神分裂症:来自医疗保健利用指数的初步证据

获取原文
获取外文期刊封面目录资料

摘要

© 2020 Physicians Postgraduate Press, IncBackground: Clozapine is indicated for treatment-resistant schizophrenia (TRS), but only 30–60 of patients will respond. There have been studies of clozapine augmentation with oral second-generation antipsychotics with mixed results, but no studies considering the combination with long-acting injectable antipsychotics (LAIAs). This study is the first to attempt to establish the benefits of the combination of clozapine and LAIAs in TRS using a variety of outcome measures of symptomatology and quality of life. Methods: A mirror-image study design was employed to review outcome measures 2 years pre and post combination of clozapine with a LAIA in a small sample of patients with chronic schizophrenia or schizoaffective disorders followed by the assertive community treatment service in the community. Outcome measures include demographic data, Brief Psychiatric Rating Scale, Clinical Global Impressions Scale–Improvement and Severity, 24-item Behavior and Symptom Identification Scale, World Health Organization Quality of Life Scale, Health of the Nation Outcome Scales, Threshold Assessment Grid, number of admissions, emergency department (ED) visits, and hospital bed days. Results: Paired sample t tests showed a statistically significant reduction in average ED visits and hospital admissions in the 2 years post combination, with an average 1.8 fewer ED visits (95 CI, 0.58– 3.02, P = .024) and a mean reduction of 0.85 hospital admissions (95 CI , 0.363–1.337, P = .008). The reduction in hospital bed days post combination was not statistically significant. Chart reviews found insufficient data for analysis of the remaining outcome measures. Conclusions: The combination of clozapine and a long-acting injectable antipsychotic appears to reduce health care utilization in terms of ED visits and number of hospital admissions. Larger prospective studies will be required to confirm the results.
机译:© 2020 医师研究生出版社背景:氯氮平适用于难治性精神分裂症 (TRS),但只有 30%-60% 的患者会有反应。已有研究使用口服第二代抗精神病药增强氯氮平,结果喜忧参半,但没有研究考虑与长效注射抗精神病药 (LAIA) 联合使用。本研究首次尝试使用症状学和生活质量的各种结果测量来确定氯氮平和 LAIA 联合治疗 TRS 的益处。方法:采用镜像研究设计来评价氯氮平与 LAIA 联合治疗前后 2 年的结果测量,这些患者在小样本中患有慢性精神分裂症或分裂情感性障碍,随后在社区中接受积极的社区治疗服务。结果测量包括人口统计数据、简要精神病学评定量表、临床总体印象量表——改善和严重程度、24 项行为和症状识别量表、世界卫生组织生活质量量表、国家健康结果量表、阈值评估网格、入院人数、急诊科 (ED) 就诊和住院天数。结果:配对样本 t 检验显示,在联合后 2 年内,平均急诊就诊和住院率有统计学意义的减少,急诊就诊平均减少 1.8 次(95% CI,0.58-3.02,P = .024),平均减少 0。85例住院(95%CI,0.363–1.337,P = 0.008)。联合用药后住院天数的减少无统计学意义。图表审查发现没有足够的数据来分析其余的结局指标。结论:氯氮平和长效注射用抗精神病药的组合似乎降低了急诊就诊次数和住院人数方面的医疗保健利用率。需要更大规模的前瞻性研究来确认结果。

著录项

  • 来源
  • 作者单位

    Department of Psychiatry Foothills Medical Centre University of Calgary;

    Department of Psychiatry South Health Campus University of Calgary;

    Decision Support Team Addiction and Mental HealthDepartment of Psychiatry Assertive Community Treatment ServiceDepartment of Psychiatry University of Calgary Cumming School of Medicine;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号